Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 3,295 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Head and Neck Cancer Clear all
Completed Phase 2 Interventional

Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach

NCT00020761
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
irinotecan hydrochloride, paclitaxel
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 17, 2026, 7:26 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers

NCT05108870
View directory record Official record
Conditions
Human Papilloma Virus, HPV, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer
Interventions
HB-201, HB-202, Carboplatin, Paclitaxel, Transoral Robotic Surgery
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 17, 2026, 7:26 AM EDT
Recruiting Phase 2 Interventional

A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)

NCT05576974
View directory record Official record
Conditions
Head and Neck Cancer, Unknown Primary Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
Pegsitacianine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 17, 2026, 7:26 AM EDT
Completed No phase listed Observational

A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)

NCT05068609
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Mount Laurel, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 17, 2026, 7:26 AM EDT
Completed No phase listed Observational

Lymph Node Assessment Using Simultaneous 18F-FDG-PET and MRI

NCT02180308
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
PET/MRI
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 17, 2026, 7:26 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Defining TRPV4 Contribution of Schwann Cells to Oral Cancer Pain

NCT07095608
View directory record Official record
Conditions
Oral Cancer, Squamous Cell Carcinoma
Interventions
Pressure and stretch sensitivity testing
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 17, 2026, 7:26 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Efficacy of Lavender Aromatherapy on Anxiety and Pain Reduction During Awake Otolaryngologic Procedures

NCT07299474
View directory record Official record
Conditions
Inferior Turbinate Hypertrophy, Chronic Rhinosinusitis (CRS), Rhinitis, Vasomotor, Thyroid Nodules, Vocal Fold Immobility
Interventions
Lavender Aromatherapy, Placebo Aromatherapy
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 17, 2026, 7:26 AM EDT
Completed Phase 1 Interventional Results available

Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer

NCT03733210
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck, Carcinoma of the Head and Neck
Interventions
Panitumumab-IRDye800, 89-Zirconium (Zr-89) Panitumumab, Pinpoint IR IR9000 fluorescence imaging system (FIS), SPY-PHI IR9000 fluorescence imaging system (FIS), Explorer Air camera, PDE-NEO II camera, FIS-00 fluorescence imaging system (FIS), Da Vinci Firefly Imaging System, IGP-ELVIS-v4 Macroscopic Specimen Imager, Vevo 3100 LAZR-X, Pearl Triology Imaging System, Odyssey CLx Imaging System, Leica fluorescence microscope
Drug · Device
Lead sponsor
Andrei Iagaru
Other
Eligibility
19 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 17, 2026, 7:26 AM EDT
Recruiting No phase listed Observational

A Study of a New PET Scanner in People With Cancer

NCT07690917
View directory record Official record
Conditions
Non Small Cell Lung Carcinoma NSCLC, Head and Neck Cancer, Prostate Cancer
Interventions
Biograph Vision Quadra scanner, PET/CT
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 7:26 AM EDT
Completed Phase 1Phase 2 Interventional

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

NCT02335918
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed, Colorectal Cancer (CRC)-Enrollment Completed, Renal Cell Carcinoma (RCC) (Phase ll Only), Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed
Interventions
Combination of varlilumab and nivolumab
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
19
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 17, 2026, 7:26 AM EDT
Completed Phase 3 Interventional Results available

Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT

NCT01931150
View directory record Official record
Conditions
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma
Interventions
Topical Dapsone 5% Gel, Moisturizer, oral antibiotics
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 17, 2026, 7:26 AM EDT
Completed Phase 1 Interventional

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

NCT03841110
View directory record Official record
Conditions
Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma
Interventions
FT500, Nivolumab, Pembrolizumab, Atezolizumab, Cyclophosphamide, Fludarabine, IL-2
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
San Diego, California • Minneapolis, Minnesota • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated May 1, 2023 · Synced Oct 17, 2026, 7:26 AM EDT
Recruiting Phase 1 Interventional

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

NCT06211335
View directory record Official record
Conditions
Locally Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma
Interventions
Losartan, Pembrolizumab, Stereotactic Body Radiation Therapy
Drug · Biological · Radiation
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Sacramento, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 17, 2026, 7:26 AM EDT
Terminated Phase 1 Interventional

Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

NCT04624113
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Tazemetostat, Pembrolizumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 17, 2026, 7:26 AM EDT
Suspended Not applicable Interventional

PET-CT Imaging With PCD-CT

NCT07242690
View directory record Official record
Conditions
Head and Neck Cancer (H&N)
Interventions
PCD-CT, PET CT
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 17, 2026, 7:26 AM EDT
Completed Phase 2 Interventional

Study to Determine the Effects Treatment With Amlexanox 0.5% Oral Rinse Solution on Oral Mucositis Associated With Radiation Therapy for Cancer of the Head and Neck Region

NCT01083875
View directory record Official record
Conditions
Oral Mucositis
Interventions
amlexanox, Vehicle rinse
Drug
Lead sponsor
Access Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
12
States / cities
Mobile, Alabama • Little Rock, Arkansas • Bakersfield, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2010 · Synced Oct 17, 2026, 7:26 AM EDT
Recruiting Not applicable Interventional

Tongue-out Radiation Therapy (TORT) for the Mitigation of Radiotherapy-related Toxicities in Patients With Head and Neck Cancer

NCT07227792
View directory record Official record
Conditions
Head and Neck Carcinoma
Interventions
Tongue-out radiation therapy (TORT)
Radiation
Lead sponsor
Yvonne Mowery
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 17, 2026, 7:26 AM EDT
Withdrawn Phase 1 Interventional

Safety Study on the Transfer of the CD40 Ligand Gene (AdcuCD40L) to Patients With Esophageal Carcinoma

NCT00328887
View directory record Official record
Conditions
Esophageal Neoplasms
Interventions
CD40 Gene Transfer
Genetic
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Ridgewood, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 17, 2026, 7:26 AM EDT
Recruiting Phase 2 Interventional

Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma

NCT06254911
View directory record Official record
Conditions
Oropharynx Cancer, Stage I
Interventions
Atezolizumab, Transoral Surgery with cervical lymphadenctomy (neck dissection), Computed Tomography, Magnetic Resonance Imaging
Biological · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 17, 2026, 7:26 AM EDT
Active, not recruiting Phase 2 Interventional

MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients

NCT04651634
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Oral Mucositis
Interventions
MIT-001 plus CCRT
Drug
Lead sponsor
MitoImmune Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Gilbert, Arizona • Los Angeles, California • Wichita, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 17, 2026, 7:26 AM EDT
Completed No phase listed Observational

Reconstructive Surgery For Head And Neck Cancer Patients

NCT00578032
View directory record Official record
Conditions
Advanced Stage Head and Neck Cancer
Interventions
Quality of Life Questionaires & Interview: EORTC QLQ C-30, EORTC QLQ H&N-35, Health Behaviors, Subjective Significance Questionnaire, Qualitative Assessment
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 17, 2026, 7:26 AM EDT
Completed Not applicable Interventional

Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma

NCT00040911
View directory record Official record
Conditions
Brain Tumors, Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Lymphoma, Nausea, Vomiting, Neuroblastoma, Ovarian Cancer, Sarcoma
Interventions
electroacupuncture therapy, sham intervention, quality-of-life assessment
Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
5 Years to 35 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Oct 17, 2026, 7:26 AM EDT
Completed Not applicable Interventional Results available

Single-arm Phase II Study of NDURE for Patients With HNC

NCT03821064
View directory record Official record
Conditions
Cancer of Head and Neck
Interventions
Patient Navigation
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 17, 2026, 7:26 AM EDT
Withdrawn Phase 2 Interventional

PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing

NCT03423264
View directory record Official record
Conditions
Oropharyngeal Cancer, HPV-Related Squamous Cell Carcinoma
Interventions
Gabapentin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 17, 2026, 7:26 AM EDT